Stoke Therapeutics, Inc. (STOK) Misses Q2 EPS by 16c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/29/2026
- Wall St set for lower open as Alphabet results reignite AI spending fears
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
- Microsoft rises premarket as cloud strength drives earnings beat
- Caterpillar shares slump 10% despite earnings beat amid rapid AI buildout
- DoorDash to acquire Instacart in $17 billion deal
Tweet
Share
E-mailGet Alerts STOK Hot Sheet
Join SI Premium – FREE
Stoke Therapeutics, Inc. (NASDAQ: STOK) reported Q2 EPS of ($0.93), $0.16 worse than the analyst estimate of ($0.77). Revenue for the quarter came in at $9.33 million versus the consensus estimate of $5.19 million.
For earnings history and earnings-related data on Stoke Therapeutics, Inc. (STOK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Stagwell Inc (STGW) Tops Q3 EPS by 3c ; Offers Guidance
- Williams-Sonoma (WSM) PT Lowered to $259 at RBC Capital
- Cantor Fitzgerald Reiterates Overweight Rating on ServiceNow (NOW)
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
